Cost-cutting, check. Now, it’s on to dealmaking, Teva chief says

Carly Helfand Teva is ready to make some deals now. It's a mantra that's seen quite a bit of play since CEO Erez Vigodman took up the reins at the generics giant early last ...

Branded drug prices leapt almost 15% last year, led by pain pills, COPD and heart meds

Carly Helfand It's no secret that branded drugmakers often rely on price hikes to keep U.S. sales growth coming, especially on older meds whose patents are close to the ends of ...

Incoming Takeda chief ready to jump on the M&A train with reorg in place

Carly Helfand Step one for incoming Takeda CEO Christophe Weber: Reorganize. Step two? Scout deals, he said Wednesday. FiercePharma News

Scandal-plagued Salix said to consider a sale

Damian Garde Salix Pharmaceuticals, marred by an embarrassing inventory scandal, has hired an investment bank to help it find some strategic alternatives, Reuters reports, including ...

Singapore to detail trial of MicroVAX novel cancer vaccine

EJ Lane The National Cancer Centre of Singapore will brief on the status of a first-in-human clinical trial using an adenovirus under a protocol endorsed by the U.S. Food and Drug Administration ...

Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit’s spinoff

Carly Helfand It's new year, new company for Reckitt Benckiser's pharma unit, spun off into Indivior last week. And while 2015 might not be the easiest for the newly minted ...

With Roche out the door, Chiasma is raising $56M to go it alone

Damian Garde In early 2013, Roche signed a $ 595 million deal with Israel's Chiasma with eyes on its promising treatment for the hormone disorder acromegaly. But the Swiss drugmaker ...

We publish, you pick: FiercePharma’s 10 best-read stories of 2014

Tracy Staton In pharma, here are the top 10 news stories of the year so far, based on web traffic. FiercePharma News

GSK shareholders to vote on Novartis megadeal in December

Carly Helfand Glaxo shareholders will soon have the chance to weigh in on an asset swap between GlaxoSmithKline and Novartis worth more than $ 20 billion. FiercePharma News

AstraZeneca earmarks $200M to support its burgeoning biologics pipeline

Damian Garde Thanks in part to its all-hands approach to immuno-oncology, AstraZeneca's pipeline is now nearly 50% biologics, leading the company to lay out $ 200 million to build ...

EU’s top regulator canned on a technicality

Damian Garde The European Medicines Agency didn't follow procedure when it appointed Executive Director Guido Rasi, a court has ruled, forcing the continent's top drug regulator ...

Some psych experts want FDA to yank black-box warning on antidepressants

Emily Wasserman In the 10 years since the FDA found that antidepressants carried an increased risk of suicidal thoughts and behaviors in teens and slapped a black box warning on the ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS